NEW: No-Cost Streetwise Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


News Update

Biotech Develops Oral Film Strips for Psychedelic Medicine Delivery

News Update
  ()
This development is a technical milestone for Revive Therapeutics and its drug delivery technology. read more >

Eyenovia Shares Look 38% Higher on Development Deal with Arctic Vision in Asia

  ()
Shares of Eyenovia Inc. set a new 52-week high after the firm reported it entered into an exclusive collaboration and license agreement with Arctic Vision to develop and market MicroPine and MicroLine in China and South Korea. read more >

Seres Therapeutics Shares Go Parabolic on Positive Topline Data from Phase 3 C.Diff Trial

  ()
Seres Therapeutics shares traded 350% higher setting a new 52-week high after the firm reported positive topline results from its SER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection. read more >

Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space?

Contributed Opinion
  ()
Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile. read more >
News Update

Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial

News Update
  ()
Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. read more >
News Update

Biopharma Preparing to Initiate Phase 3 COVID-19 Trial

News Update
  ()
Revive Therapeutics is now "finalizing agreements and aligning resources to initiate the Phase 3 clinical trial in September." read more >

Denali Shares Rise 37% on Advancement of DNL151 into Late Stage Parkinson's Trials

  ()
Shares of Denali Therapeutics reached a new 52-week high after the company reported plans to advance DNL151 in two separate late stage Parkinson's disease clinical studies with its partner Biogen. read more >
News Update

Biopharma Gets FDA Approval for Phase 3 COVID-19 Trial

News Update
  ()
Revive Therapeutics' trial will test Bucillamine in patients with mild to moderate COVID-19. read more >

Ten Good Reasons to Invest Now Pre-Market in Acurx Pharmaceuticals

Contributed Opinion
  ()
Dr. KSS, the founder and editor-in-chief of BioPub.co, provides his investment thesis for a company that is promulgating the first new class of antibiotics in 30 years. read more >

Kodak Shares Triple in a Flash on $765 Million Loan from DFC for New Pharmaceutical Unit

  ()
Eastman Kodak shares traded more than 200% higher after the company reported it is forming a new business unit to produce essential pharmaceutical components funded by the U.S. International Development Finance Corporation. read more >

TCR2 Therapeutics Reports Positive Results in Mesothelin-Expressing Solid Tumor Study

  ()
Shares of TCR2 Therapeutics traded 30% higher after the firm released encouraging results from the Phase 1 portion of its clinical study of TC-210 in treating advanced mesothelin-expressing solid tumors. read more >

Milestone Shares More than Double After Presenting Updated Clinical Plan for Heart Condition

  ()
Shares of Milestone Pharmaceuticals traded 150% higher after the company reported regulatory guidance and updated its clinical development plan for etripamil nasal spray designed for self-administered use in PSVT treatment. read more >

Biopharma's Therapeutic Jumps to Phase 2 Testing for COVID-19 'to Shut Down the Cytokine Storm'

Research Report
  ()
A development update on Sorrento Therapeutics' three coronavirus-related products is provided in a Dawson James report. read more >

Dynavax Shares Rise 20% on Partnership with Mount Sinai to Develop Universal Flu Vaccine

  ()
Shares of Dynavax Technologies reached a new 52-week high after the company reported that it is collaborating with Mount Sinai to develop a universal influenza vaccine candidate with CpG 1018 adjuvant. read more >

AC Immune Shares Rise 19% as Firm Advances Alzheimer's Vaccine in Phase 1b/2a Trial

  ()
AC Immune SA shares set a new 52-week high after the Swiss biotech firm reported that interim data from its Phase 1b/2a phospho-Tau Alzheimer's Vaccine study reconfirms promising safety and Tau-specific immunogenicity observed in the prior clinical trial. read more >

Taiwan Liposome Shares Rise 60% on Inhalable Liposomal HCQ Potential Covid-19 Treatment Claims

  ()
Shares of Taiwan Liposome Co. reached a new 52-week high after the company released a manuscript describing how its inhalable liposomal hydroxychloroquine may provide clinical benefit and offer a potential treatment for Covid-19. read more >

INmune Bio Shares Double after Reporting Positive Phase 1b Alzheimer's Trial Data

  ()
Shares of INmune Bio reached a new 52-week high after the company reported interim data from its Phase 1b study of XPro1595 that demonstrated decreased neuroinflammation in Alzheimer's patients. read more >

Potential Covid-19 Treatment Is Ready for Prime Time

  ()
Small-cap Algernon Pharmaceuticals is about to begin a multinational Phase 2b/3 trial for Ifenprodil, a repurposed drug with a known safety record. read more >

BioNTech Shares Rise as FDA Grants It and Partner Pfizer Fast Track Status for Two Covid-19 Vaccine Candidates

  ()
Shares of BioNTech SE traded 15% higher after the company reported that, together with its partner Pfizer, it has received FDA Fast Track designation for two separate mRNA-based vaccine candidates against SARS-CoV-2. read more >
News Update

Threat Detection Company Forms Partnership to Advance Covid-19 Pathogen Screening

News Update
  ()
Patriot One Technologies reported it is collaborating with ecoMine Technologies to advance pathogen screening applications as part of Canada's Digital Technology Supercluster's Covid-19 program. read more >

Altimmune Shares Up 20% Upon Forming Partnership for Intranasal COVID-19 Vaccine

  ()
Altimmune shares reached a new 52-week high after the company reported it is collaborating with DynPort Vaccine on U.S. government funding efforts for AdCOVID™, its COVID-19 vaccine candidate. read more >

Biotech with Phase 3 Rheumatoid Arthritis and Psoriasis Trials Raises Capital, Now 'Funded Through Catalysts'

Research Report
  ()
An update on Can-Fite BioPharma's multiple drug treatment trials is provided in a Dawson James report. read more >

Preclinical COVID-19 Vaccine Data 'Encouraging'

Research Report
  ()
Updates on Sorrento Therapeutics' two coronavirus-related products are provided in an H.C. Wainwright & Co. report. read more >
News Update

Biopharma Starts Enrollment Screening for Phase 2 Pulmonary Fibrosis, Cough Trial

News Update
  ()
In the study, Algernon Pharmaceuticals will test an existing drug that is being repurposed for these indications. read more >

Analyst: G1 Minimizes the Carnage of Chemotherapy

Research Report
  ()
ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. read more >
Showing Results: 1 to 25 of 109 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"HIGH drill program expansion includes mobilization of a third rig." ❭
– Gwen Preston, Resource Maven
"GSV has about $15–20M after Orion's purchases and sale of the stream." ❭
– Andrew Mikitchook, M Partners
"ELY acquired an additional 1% NSR royalty on Lincoln Hill." ❭
– Mark Reichman, Noble Capital Markets
"POE was drilling water but found a good oil zone!" ❭
– Chen Lin, What Is Chen Buying? What Is Chen Selling?
"ABN stock looks like it is at a great Buy spot here." ❭
– Clive Maund, CliveMaund.com